PVI
Pura Vida Investments Portfolio holdings
AUM
$16.6M
This Quarter Return
+5.37%
1 Year Return
-3.82%
3 Year Return
-0.02%
5 Year Return
+29.84%
10 Year Return
+256.58%
AUM
$596M
AUM Growth
+$596M
(-10%)
Cap. Flow
-$99.1M
Cap. Flow
% of AUM
-16.61%
Top 10 Holdings %
Top 10 Hldgs %
55.37%
Holding
215
New
32
Increased
15
Reduced
34
Closed
44
Top Buys
| 1 |
Biogen
BIIB
|
$16M |
| 2 |
SONX
Sonendo, Inc.
SONX
|
$11M |
| 3 |
Azenta
AZTA
|
$7.34M |
| 4 |
Quanterix
QTRX
|
$7.09M |
| 5 |
Natera
NTRA
|
$6.63M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$24.7M |
| 2 |
Cytokinetics
CYTK
|
$12.6M |
| 3 |
Outset Medical
OM
|
$11.6M |
| 4 |
Illumina
ILMN
|
$10.5M |
| 5 |
AstraZeneca
AZN
|
$9.6M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.83% |
| 3 | Consumer Staples | 0% |
| 4 | Financials | 0% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICAD
51
DELISTED
iCAD Inc
ICAD
| $2.03M | 0.1% |
1,108,669
+228,111
| +26% | +$417K |
|
52
Esperion Therapeutics
ESPR
$490M
| $1.92M | 0.1% |
308,313
-23,810
| -7% | -$148K |
|
|
AVDL
53
Avadel Pharmaceuticals
AVDL
$1.42B
| $1.86M | 0.1% |
260,000
+174,242
| +203% | +$1.25M |
|
54
Annexon
ANNX
$225M
| $1.57M | 0.08% |
302,734
-71,896
| -19% | -$372K |
|
55
SOPHiA GENETICS
SOPH
$232M
| $1.55M | 0.08% |
754,036
-142,204
| -16% | -$293K |
|
56
GH Research
GHRS
$870M
| $1.54M | 0.08% |
158,327
| – | – |
|
57
Milestone Pharmaceuticals
MIST
$151M
| $1.47M | 0.08% |
371,788
-224,743
| -38% | -$890K |
|
|
HZNP
58
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $1.47M | 0.08% |
12,900
| – | – |
|
59
Apyx Medical
APYX
$71.9M
| $1.42M | 0.07% |
607,560
-900,502
| -60% | -$2.11M |
|
60
Liquidia Corp
LQDA
$2.52B
| $1.33M | 0.07% |
208,535
-329,335
| -61% | -$2.1M |
|
61
Alkermes
ALKS
$4.95B
| $1.31M | 0.07% |
50,000
| – | – |
|
62
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.22M | 0.06% |
106,629
-170,000
| -61% | -$1.95M |
|
|
CNCE
63
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.21M | 0.06% |
+206,525
| New | +$1.21M |
|
64
Exelixis
EXEL
$9.95B
| $1.2M | 0.06% |
75,000
| – | – |
|
65
ADMA Biologics
ADMA
$4.03B
| $1.16M | 0.06% |
+300,000
| New | +$1.16M |
|
66
Viridian Therapeutics
VRDN
$1.59B
| $1.02M | 0.05% |
35,003
-40,000
| -53% | -$1.17M |
|
67
Arcturus Therapeutics
ARCT
$467M
| $848K | 0.04% |
+50,000
| New | +$848K |
|
68
Pacific Biosciences
PACB
$378M
| $818K | 0.04% |
+100,000
| New | +$818K |
|
69
Vertex Pharmaceuticals
VRTX
$102B
| $809K | 0.04% |
2,800
-23,963
| -90% | -$6.92M |
|
|
NYXH
70
Nyxoah
NYXH
$220M
| $801K | 0.04% |
149,131
-72,818
| -33% | -$391K |
|
71
CureVac
CVAC
$1.21B
| $774K | 0.04% |
+128,245
| New | +$774K |
|
72
Stevanato
STVN
$6.36B
| $755K | 0.04% |
+42,000
| New | +$755K |
|
|
MACK
73
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $735K | 0.04% |
+64,100
| New | +$735K |
|
74
Avantor
AVTR
$8.74B
| $732K | 0.04% |
+34,700
| New | +$732K |
|
75
Vera Therapeutics
VERA
$1.47B
| $684K | 0.04% |
+35,372
| New | +$684K |
|